Bionexus Gene Lab Corporation was the first Nasdaq-listed company Ethereum (ETH) to Bitcoin (BTC) chosen as strategic property in the business reserves. With this step, Bionexus puts himself on the map as a pioneer within the financial strategies of tech companies.
Ethereum as a source of income
The Techonderneming from Asia published his Ethereum Strategy WhitePaper on Wednesday. It explains why Ethereum is preferred. It is not only seen as a storage of value, but especially as a platform with broad financial applications.
An important reason for this choice is the possibility to generate returns through a strike. Whereas Bitcoin remains a passive possession, Ethereum yields an extra income flow via the proof-of-stake mechanism. According to Bionexus, this can yield 3-5% returns annually, which means Ethereum turns into an actively managed investment.
Ethereum’s Institutional Position and Technological Progress
In addition to returns and usability, Bionexus points to the increasing adoption of Ethereum through major financial institutions such as BlackRock and Fidelity, which launched their own spot stock market funds on the American market last year. This is seen as confirmation of Ethereum’s long -term potential within the financial sector.
In addition, Ethereum plays a major role in transactions with stablecoins. The network processes billions of dollars annually on USDT, USDC and other Stablecoin transactions. This underlines the growing significance of Ethereum as a fundamental building block of the global financial infrastructure.
The company also refers to the upcoming pectra upgrade, which has to make Ethereum even more reliable and more stable. Yesterday it went live on the Sepolia Testnet and today there may be more information when it is the turn of the Mainnet.
Nasdaq warning: Bionexus must restore course
Despite the ambitious plans with Ethereum, Bionexus is struggling with financial problems. In December it received a warning from the Nasdaq because the share price was under the required $ 1 per share.
To comply with the stock market rules, the company has until 1 May 2025 to restore the course. As part of this plan, a reverse stock split is planned before 7 April 2025.
Bionexus reported a turnover of $ 9.26 million over the past twelve months, while the Market Cap is $ 5.88 million. At the time of writing, the share of Bionexus records $ 0.3416. An increase of 4.37% in the last 24 hours.
Claim € 10 free today and do not pay trading costs over the first € 10,000!
Grab this unique opportunity with Newsbit and Bitvavo by creating an account now via the button below. Only deposit € 10 and receive € 10 free of charge. Moreover, you can act without costs for 7 days over your first € 10,000 in transactions. Start today and take advantage of the growing popularity of Crypto!
Make your account and claim € 10 for free.
Don’t miss this opportunity to take advantage of the growing popularity of Crypto!
Source: https://newsbit.nl/dit-nasdaq-bedrijf-kiest-ethereum-als-strategische-reserve/
